FINWIRES · TerminalLIVE
FINWIRES

Avnet 'Cycle' Trends Improve as Backlog Extends, Lead Times Lengthen, BofA Says

By

Avnet (AVT) is showing improving industry "cycle" trends as "backlog" extends further out, "book-to-bill" ratios remain above 1 across all regions and lead times are lengthening in more than half of tracked product categories, BofA Securities said in a report Wednesday.

"Inventory correction" appears to have largely passed its trough, with Avnet showing "clear upcycle patterns" as inventory normalized to 77 days. The company is "entering the upcycle" with a cleaner balance sheet than in prior cycles, according to the report.

The firm also pointed to improving operating leverage as selling, general and administrative expenses declined to 70.2% of gross profit from 74.2% in the previous quarter.

Avnet's Farnell "catalog business" is also recovering and could see 50 to 100 basis points of sequential operating margin improvement as product mix improves and "cost discipline" continues, though the report said "demand remains uneven."

BofA upgraded Avnet to neutral from underperform and raised its price target to $96 from $66.

The firm cautioned that weaker end-market demand in the second half of 2026 and in 2027, slower recovery in Europe and Farnell, unfavorable "regional mix" and elevated Wall Street expectations could limit upside.

Price: $84.72, Change: $+2.61, Percent Change: +3.17%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP